AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$BLLN

ten Bosch John Roderick sold $138K of BLLN

ten Bosch John Roderick (SVP of Laboratory Operations) sold 1,416 shares of BillionToOne, Inc. (BLLN) at $97.54 ($0.14M total) on 2026-09-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ten Bosch John Roderick
Published Sep 11, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
high confidence
Mentioned
$BLLN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting minimal immediate market reaction.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming dilution events or financing not disclosed.

Relevance 3/10Novelty 4/10Timing: filed Sep 11 2026

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$BLLNNeutralHigh confidence
Context

Officer John Roderick sold 1,416 shares for $138,116 via a 10b5-1 plan.

Expected impact

No significant move expected.

Evidence & confidence

Sale size is small relative to market cap and disclosed via pre‑arranged plan.

Market effects

Sector

None; insider sale does not affect sector trends.

Regional

None; company is micro‑cap with limited broader impact.

Global

None

Counterpoint

What could challenge this read

Sale could signal insider concern, but 10b5‑1 plans are routine.

Key entities

  • Company
    BillionToOne, Inc.

    Issuer of the disclosed insider transaction.

  • Insider
    John Roderick

    SVP of Laboratory Operations who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLLN insider trading history →

Related articles

AUG 6
$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

benzinga.com3 min
MAY 27
$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.

dailypolitical.com1 min